Vol 50 No 05

"As we celebrate 50 years of successes, the Gleason grading system deserves recognition," writes Michael S. Cookson, MD, MMHC.

Labs will need to apply for unique Z code for each panel of tests ordered.

Insurance company contributed to settlement without insured’s consent.

"It’s very possible that the PSA screening-detected high-risk prostate cancer portends a more favorable outlook when compared with the pre-PSA era, regardless of the type of primary therapy utilized," writes Badar M. Mian, MD.

Surgical approach and ischemia time are among key topics.

Ekene Enemchukwu, MD, MPH, highlights her presentation, "Microaggressions 2.0 – How to survive and thrive," from the 2022 SUFU winter meeting.

Which option you select depends on your goals and what you want to cover.

In this installment of Urology Times' 50th Anniversary Innovation Celebration, James E. Lingeman, MD, discusses the development of extracorporeal shock wave lithotripsy for the treatment of kidney stones.

At the 2022 NY GU Cancers Symposium, Jean Hoffman-Censits, MD, discussed the latest developments in the neoadjuvant and adjuvant setting for patients with bladder cancer.

"We shouldn't outright provide a negative attitude to our patients who are looking for alternatives that [serve as] complementary medicine, [like] herbal or phytotherapeutic agents," says J. Curtis Nickel, MD, FRCSC.